Targeting Innovation.

—CONTINUE READING

Radically improving diabetes treatment efficiency.

The fear of hypoglycemia, or low blood sugar, is a central challenge for people with diabetes.
Diasome was founded and is led by a diverse collection of breakthrough thinkers and doers in both the science and business communities.
Diasome’s vision is to significantly reduce hypoglycemia risk by enabling every unit of insulin to better work with the body’s normal metabolic system. This should make all insulins more effective and much safer.

Hepatocytes’ Unique Role

The liver’s hepatocytes are the only cells in the entire body that can both store sugar during a meal to prevent hyperglycemia and release sugar during the rest of the day to prevent hypoglycemia. But, hepatocytes will only function in this way if they receive insulin in the right amount at the right time. This is extremely difficult to achieve when insulin is injected under the skin because of the tendency of subcutaneous insulin to be taken up by muscle and fat cells before reaching the liver.

Diasome’s HDV System

HDV is a globally-patented, Phase 2b-stage nano-sized liver cell targeting system that can be added very simply to any form of commercially available insulin. Diasome’s Hepatocyte Directed Vesicles (HDV) liver targeting system is designed to minimize hypoglycemia by enabling the body’s natural glucose metabolism mechanism, based in liver hepatocytes, to function more normally during insulin therapy. HDV enables more injected insulin to reach its target in the liver.

Management Team

Board of Directors

People.

Robert Geho CEO
W. Blair Geho, MD, PhD Chief Scientific Officer
Marc S. Penn, MD, PhD Chief Medical Officer
Douglas B. Muchmore, MD Chief Technology Officer
Christine Smith, PhD Chief Manufacturing Officer
Helga Kautsky, CPA Chief Financial Officer
Kerry Watterson Corporate Development

Robert Geho
W. Blair Geho
Marc S. Penn
Frank McCaney
Thomas McDonald

Scientific Advisory Board

Bruce Bode, MD
Jeremy Pettus, MD
Robert Henry, MD

Latest Updates.

View our press releases and follow Diasome’s path to Phase III Clinical Trials.

Press Release

February 14, 2019

Diasome Pharmaceuticals, Inc. provides 16-month period company update

Learn More

Press Release

February 14, 2019

Diasome Pharmaceuticals, Inc. provides 16-month period company update

Learn More

Press Release

July 5, 2017

Diasome Pharmaceuticals, Inc. Receives Funding From JDRF T1D Fund

Learn More

Press Release

July 5, 2017

Diasome Pharmaceuticals, Inc. Receives Funding From JDRF T1D Fund

Learn More

Press Release

July 5, 2017

Diasome Pharmaceuticals, Inc. Receives Funding Led By Medicxi

Learn More

Press Release

July 5, 2017

Diasome Pharmaceuticals, Inc. Receives Funding Led By Medicxi

Learn More

Interview

September 17, 2016

2016 Diabetes Symposium in Boston, Robert Geho interviewed by Diabetes in Control publisher Steve Freed

Learn More

Interview

September 17, 2016

2016 Diabetes Symposium in Boston, Robert Geho interviewed by Diabetes in Control publisher Steve Freed

Learn More

News Article

August 28, 2016

After Decades of work, Diasome's insulin additive enters 200-patient trial

Learn More

News Article

August 28, 2016

After Decades of work, Diasome's insulin additive enters 200-patient trial

Learn More

Press Release

July 29, 2016

Diasome announces dosing of first type 1 diabetes patient in randomized phase 2b clinical trial of injectable hepatocyte direct vesicle (HDV) technology with insulin

Learn More

Press Release

July 29, 2016

Diasome announces dosing of first type 1 diabetes patient in randomized phase 2b clinical trial of injectable hepatocyte direct vesicle (HDV) technology with insulin

Learn More

Press Release

March 15, 2016

Diasome Pharmaceuticals, Inc. and Lyfebulb, LLC Announce Partnership

Learn More

Press Release

March 15, 2016

Diasome Pharmaceuticals, Inc. and Lyfebulb, LLC Announce Partnership

Learn More

Journal Article

May, 2014

The importance of the liver in insulin replacement therapy in insulin-deficient diabetes

Learn More

Journal Article

May, 2014

The importance of the liver in insulin replacement therapy in insulin-deficient diabetes

Learn More

Study Summary

February 27, 2014

A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral anti-diabetic treatment in patients with type 2 diabetes mellitus

Learn More

Study Summary

February 27, 2014

A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral anti-diabetic treatment in patients with type 2 diabetes mellitus

Learn More

Press Release

April 27, 2015

Clinical trial design collaboration with Joslin Diabetes Center

Learn More

Press Release

April 27, 2015

Clinical trial design collaboration with Joslin Diabetes Center

Learn More

Press Release

March 31, 2015

Injected HDV insulin patent allowance

Learn More

Press Release

March 31, 2015

Injected HDV insulin patent allowance

Learn More

Press Release

February 25, 2015

Oral insulin technology patent issues

Learn More

Press Release

February 25, 2015

Oral insulin technology patent issues

Learn More

Press Release

April 9, 2014

McDonald Partners Engagement

Learn More

Press Release

April 9, 2014

McDonald Partners Engagement

Learn More

Journal Article

July 1, 2013

The preparation and evaluation of tritiated polyalanyl insulin derivates

Learn More

Journal Article

July 1, 2013

The preparation and evaluation of tritiated polyalanyl insulin derivates

Learn More

Press Release

March 6, 2013

Weight loss patent allowance

Learn More

Press Release

March 6, 2013

Weight loss patent allowance

Learn More

Journal Article

November, 2009

Hepatic-Directed Vesicle Insulin: a review of formulation development and preclinical evaluation

Learn More

Journal Article

November, 2009

Hepatic-Directed Vesicle Insulin: a review of formulation development and preclinical evaluation

Learn More

Study Summary

January 9, 2009

Clinical trial summary: Single-Blind, Placebo-Controlled, Dose-Ranging trial of Oral HDV-Insulin in Patients with type 2 Diabetes Mellitus

Learn More

Study Summary

January 9, 2009

Clinical trial summary: Single-Blind, Placebo-Controlled, Dose-Ranging trial of Oral HDV-Insulin in Patients with type 2 Diabetes Mellitus

Learn More

Study Summary

June, 2008

A Two-Week randomized active comparator study of two HDV-Insulin routes (SC and Oral) and SC Human Insulin in Patients with Type 1 Diabetes Mellitus

Learn More

Study Summary

June, 2008

A Two-Week randomized active comparator study of two HDV-Insulin routes (SC and Oral) and SC Human Insulin in Patients with Type 1 Diabetes Mellitus

Learn More

Study Summary

June, 2008

Hepatic-Directed Vesicles-Insulin: Evaluation of a Novel Oral and Subcutaneous Insulin Delivery System in Animal Models of Diabetes

Learn More

Study Summary

June, 2008

Hepatic-Directed Vesicles-Insulin: Evaluation of a Novel Oral and Subcutaneous Insulin Delivery System in Animal Models of Diabetes

Learn More

Journal Article

March 30, 2001

The effects of HDV-Insulin on carbohydrate metabolism in Type 1 Diabetic patients

Learn More

Journal Article

March 30, 2001

The effects of HDV-Insulin on carbohydrate metabolism in Type 1 Diabetic patients

Learn More